Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

You are viewing the site in preview mode

Skip to main content

Table 1 (abstract PReS24-ABS-1185). General features of the cohort

From: Proceedings of the 31st European Paediatric Rheumatology Congress: part 2

 

Overall (N=114)

No recurrences (N=61 pts)

Recurrences (N=53 pts)

p

Age, years, mean (sd)

12 (3.9)

12 (4)

12 (3.8)

0.81

Ethnicity

   

0.03

 Caucasian

74 (65%)

34 (55%)

40 (75%)

 

 Non-Caucasian

40 (35%)

27 (45%)

13 (25%)

 

Diagnosis

   

0.51

 Idiopathic Uveitis

46 (40%)

22 (36%)

24 (45%)

 

 Juvenile idiopathic arthritis

52 (46%)

28 (46%)

24 (45%)

 

 Other

16 (14%)

11 (18%)

5 (10%)

 

Inactivity before adalimumab taper onset, weeks, mean (sd)

163 (174)

189 (200)

133 (132)

0.72